drugset
drugset / Trial / NCT06771609

Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.

NCT06771609 ↗

Phase 2 Recruiting 150 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase II clinical trial of PD-L1 in combination with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy with or without radiotherapy for advanced triple-negative breast cancer.

Timeline

Start
2024-09-10
Primary completion
2028-09-10
Completion
2028-09-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adebrelimab Monoclonal antibody 1200 mg —
Comparator Capecitabine Small molecule 500 mg Oral
Comparator Cyclophosphamide Other / unclassified 50 mg Oral
Comparator Vinorelbine Small molecule 20 mg Oral

Indications

triple-negative breast carcinoma